AI-based Business Drives 32% Growth in Taoping's First Half 2024 Total Contract Revenue Value

Stock Information for China SXT Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About China SXT Pharmaceuticals Inc.

Taoping Signs Letter of Intent to Acquire Alphalion Holding, Significantly Bolsters AI-Driven Digital Ecosystem
Taoping to Acquire Skyladder Group in All-Stock Transaction Valued at RMB 152 Million
Taoping Targets FY26 Sales of Approximately US$27 Million from Smart Agriculture
Taoping Regains Compliance with Nasdaq Minimum Bid Price Requirement
Taoping Selected for New US$2.8 Million Agricultural Product Supply Contract; Company Continues to Build Momentum in Important Growth Market
Taoping Announces 1-for-30 Reverse Stock Split
Taoping Reports Full Year 2024 Financial Results
25% YoY Growth in Taoping's 1Q 2025 Total Contract Revenue Value Driven by Continued Strong Demand for AI-Related Products

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.